1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bloomios, Inc.

Bloomios, Inc.

BLMS
Bloomios, Inc.US flagOther OTC
0.00
USD
- -
- -
6,447.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2019 Y
2019 Y
2020 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.11
0.67
0.46
0.22
Basic EPS, GAAP
-0.04
-0.04
-0.01
-7.19
1.31
-0.21
- -
-0.04
- -
-0.09
-0.16
-1.04
-1.08
Free Cash Flow per Basic Share
-0.05
-0.03
-0.01
-1.8
-0.17
-0.05
- -
- -
- -
-0.12
-0.07
-0.48
-0.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.27
-0.28
-0.28
-10.07
-4.74
-5.06
-1.05
-0.25
-0.21
-0.35
-0.5
-1.52
-1.37
Tangible Book Value per Share
0.01
-0.01
0.41
-4.64
-1.2
-1.46
- -
-0.04
- -
-0.13
-0.15
-2.4
-1.08
Basic Weighted Avg Shares
1
1
1
- -
1
1
3
13
13
13
13
13
37
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
8
6
8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-80.74
-8.48
-67.13
-61.04
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-2
1
- -
- -
- -
- -
-1
-2
-14
-40
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-88.94
-23.69
-226.66
-489.86
Working Capital
- -
- -
- -
-1
-1
-1
- -
- -
- -
-3
-4
-25
-33
LT Debt
- -
- -
- -
1
- -
- -
- -
- -
- -
1
- -
- -
- -
Total Equity
- -
- -
1
-1
-1
-1
- -
- -
- -
-1
-2
-1
-31
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
23
24
24
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
8
8
8
Shares Outstanding
30
33
61
Market Capitalization
14
1
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
2
2
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
- -
- -
Inventories
2
2
- -
Total Current Liabilities
30
31
33
Payables & Accruals
6
7
8
ST Debt
23
24
24
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-15.84%
Free Cash Flow
1,269.48%
1,931.15%
608.05%
Net Income, GAAP
3,666.52%
2,440.93%
584.83%
Sales/Revenue/Turnover
- -
- -
-28.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
2
2
2
2
8
2022
1
1
1
2
6
2023
3
3
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.13
0.03
-0.02
- -
-0.16
2022
-0.1
-0.09
-0.16
- -
-1.04
2023
-0.11
-0.09
-0.42
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Michael Hill
Full Time Employees
3
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
201 West Montecito Street Santa Barbara CA United States of America 93101
IPO Date
Apr 22, 2003
CIK
0001138608
Website
bloomios.com
Similar Companies
Abattis Bioceuticals Corp. (ATTBF)
Krka, d. d. (KRK.WA)
Takeda Pharmaceutical Company Limited (4502.T)
Sawai Group Holdings Co., Ltd. (4887.T)
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
Natural Capsules Ltd. (NATCAPSUQ.NS)
Business
Bloomios, Inc. (OTCQB: BLMS) manufactures, markets, and distributes U.S. hemp-derived supplements, nutraceutical, cosmetic, and pet products through wholesale distribution channels and its wholly owned subsidiary, Bloomios Private Label. The company offers private-label and white-label customers more than 80 customizable products across seven categories, including edibles such as gummies, tinctures, oils, salves, capsules, beverages, and topicals; it provides full-service custom formulation, brand development, research and development, manufacturing, compliance solutions, and order fulfillment to small brands, major brands, chain stores, vape shops, and distributors. Bloomios serves businesses in the hemp, cannabinoid, nootropic, and nutraceutical sectors, with a focus on natural ingredients like CBD, ashwagandha, melatonin, kratom, lion's mane, valerian root, reishi mushroom, L-theanine, ginkgo biloba, caffeine, and rhodiola rosea for applications in focus, sleep, relaxation, pain relief, and inflammation. Founded in 2001 and headquartered in Santa Barbara, California, with manufacturing and distribution facilities in Daytona Beach, Florida, Bloomios operates primarily in the North American market. The company targets the growing CBD, alternative cannabinoid, skincare, and complementary medicine markets, projected to expand significantly through 2028. In October 2022, Bloomios completed a $23.5 million acquisition of Infusionz LLC, a leading gummy manufacturer and wholly owned subsidiary of Upexi Inc. (NASDAQ: UPXI), which included Infusionz's CBD gummy brands, product formulations, manufacturing operations, equipment, sales team, and customer base; the transaction more than doubled production capacity, added over $22 million in annualized gross revenue, and established a long-term manufacturing partnership with Upexi. This strategic move supported entry into the direct-to-consumer market and new distribution channels, funded in part by a $13.9 million senior secured convertible debenture offering led by institutional investors. Earlier expansions included a 300% increase in manufacturing capacity via a 50,000 sq. ft. facility in Daytona Beach and partnerships such as with DRYWORLD in sports nutrition and CMA for investor outreach.

Company News

APIChat

  • prismmediawire.com

    Bloomios Reports Q2 2023 Financial Results

  • newsfilecorp.com

    Bloomios To Present at The 2022 LD Micro Main Event October 25-27

  • prnewswire.com

    Bloomios to Present at the 2022 LD Micro Invitational June 7-9